GlassScriptPhysician profile
Paul W Roderick
NPI 1831183904
$5,065.45
in general payments reported to CMS, 2019-2025
10 companies · $4,769 in 2025
The $4,769 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2022: $92.75 · 2025: $4,769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,769.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,768.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $4,768.99 | 2025 | |
| Abbvie INC. | $119.75 | 2019-2022 | |
| Medtronic, INC. | $52.16 | 2022 | |
| Boston Scientific Corporation | $32.17 | 2019 | |
| Ucb, INC. | $28.32 | 2019 | |
| Pfizer INC. | $18.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2019 | |
| Cook Medical LLC | $12.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.36 | 2019 | |
| Qol Medical, LLC | $6.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Roderick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.